BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 17, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VIA-2291: Phase II data

In a double-blind Phase II trial in 50 patients scheduled for elective carotid endarterectomy (CEA), VIA-2291 missed the primary endpoint of reducing macrophages in carotid plaque tissue vs. placebo. VIA-2291 met secondary endpoints,...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >